Additional research is needed to determine whether this is due to direct drug effects or underlying patient factors.
Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.
Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback